Lipids in cell membranes regulate the activity of a cancer-linked protein, cell biologists at RIKEN have discovered. This ...

Boehringer Ingelheim’s drug candidate for human epidermal growth factor receptor 2 (HER2)-mutated non-small cell lung cancer ...

New research uncovers key factors driving survival and treatment response in patients with HER2-positive breast cancer ...

Topical BRAF inhibitor LUT014 gel significantly reduces acneiform rash from anti-EGFR therapies in patients with colorectal ...

The use of an investigational topical BRAF-inhibiting gel appeared to be effective in treating acneiform rash in patients ...

The trial aims to assess the safety and efficacy of Enhertu, either as a single agent or with pertuzumab, against the THP.

AstraZeneca Partners with Revna Biosciences to Enhance Epidermal Growth Factor Receptor (EGFR) Biomarker Testing in Ghana ...

The drug receives conditional marketing authorization by the CHMP for the treatment of HER2-positive biliary tract cancer.

Non-small cell lung cancer (NSCLC) remains one of the leading causes of cancer-related deaths globally, and Ghana is no ...

This collaboration will provide early-stage HER2-positive breast cancer patients with access to the targeted therapy that can ...